Comparison of pharmacodynamics and pharmacokinetics of ultra-rapid-acting insulin aspart and rapid-acting insulin aspart around continuous moderate intensity exercise in adults with type 1 diabetes: A randomised controlled trial

What Was Tested

The paper reports a study of Insulin Aspart, published as a randomized controlled trial.

Venous blood samples were taken at 5-, 10-, and 15-min epochs, for a total of 70 timepoints, throughout the trial day until 4 h after the second injection to determine blood glucose and insulin concentrations.

Who Took Part

According to the abstract, 43 adults were involved.

PubMed indexes the participants as young adults, adults and middle-aged adults, both men and women.

In this double-blind, laboratory-controlled study, 43 adults with T1D completed four experimental visits in a randomised crossover design.

How the Study Was Run

The researchers set it up as a randomized, double-blind and crossover study.

Because people in this Insulin Aspart study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the adults nor the staff measuring them knew who was on Insulin Aspart, so expectations could not easily colour the readings.

In the crossover set-up each of the adults took both Insulin Aspart and the comparison in turn, acting as their own control.

The primary endpoint was the four-way comparison of blood glucose change from exercise start to end.

What Was Measured

The subject headings attached to it are Diabetes Mellitus, Type 1, Insulin Aspart, Blood Glucose, Hypoglycemic Agents, Exercise and Insulin, Short-Acting.

The authors tagged it with the keywords insulin analogues and type 1 diabetes.

What This Means in Plain Language

The paper is a randomized, double-blind and crossover study of Insulin Aspart in 43 adults.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2026 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Insulin Aspart compound page, all human trials.